Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Tiaprid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 462 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tiaprid, ATC N05AL03

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for the medicinal product Tiaprid, ATC N05AL03.
  • Supply contract for pharmaceutical products.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement for Tiaprid (ATC N05AL03) led by AOK Bayern. It is not a competitive open procedure in substance: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2026-02-01 to 2028-01-31, with contract entry possible until 2027-12-03. Submission is via DTVP electronic channel with a qualified electronic signature, or by signed paper originals in duplicate. No contract value is stated.

Ryzyka

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit the signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • The declaration of reliability must be signed and submitted with the tender documents.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Tiaprid

Open-house non-exclusive pharmaceutical rebate agreement for Tiaprid (ATC N05AL03). Scope is supply of pharmaceutical products under a pre-set contract; the notice says the contract terms are identical and not individually negotiable. Place of performance is Germany, region DE212 (Bavaria/Munich area as indicated by buyer address and lot data).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Dec 03, 2027

Szczegóły zamówienia

Data publikacji
14 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
831717-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30